Current Treatment Options in Neurology

, Volume 15, Issue 4, pp 424–438 | Cite as

Treatment of Huntington Disease

  • Aleksandar VidenovicEmail author

Opinion statement

Many pharmacological agents have been utilized in the treatment of Huntington disease (HD). Several excellent reviews about the treatment of HD are available. Formal treatment guidelines are however lacking. This is mainly the result of limited evidence available in the literature. Further, available treatment studies are frequently hard to compare due to variable outcomes/instruments used, differences in the study population, and confounding effects of complex medication regimens. Generally speaking, the treatment paradigm for an HD patient will depend on the constellation of 3 main clinical domains affected in HD: motor, behavioral/psychiatric, and cognitive. Symptoms within each of these domains remain dynamic throughout the course of HD. It is therefore necessary to monitor patients clinically and adjust drugs accordingly as the disease progresses. The most commonly used chorea drugs are antipsychotics and tetrabenazine (TBZ). Antipsychotic drugs are preferred in patients with coexistent psychiatric/behavioral comorbidities as well as in the presence of depression. Amantadine may be considered in the treatment of chorea, but data supporting its effectiveness remain conflicting. Selective serotonin reuptake inhibitors (SSRIs) are the treatment of choice for irritability and obsessive-compulsive behaviors associated with HD. Antipsychotic agents and antiepileptic mood stabilizers may be used as add-on therapies. There is very limited evidence for the treatment of cognitive impairment associated with HD. Each drug used in treatment of HD has a potential for causing significant side effects. It is, therefore, critical to assess the risk-benefit ratio on an individual basis, and carefully monitor patients throughout the course of treatment. Non-pharmacological and surgical treatment strategies for HD have not been systematically explored. Despite the lack of evidence, behavioral interventions, as well as physical, occupational, and speech therapies may provide additional benefits to a wide spectrum of disabilities associated with HD.


Huntington disease Treatment Chorea Antidopaminergic agents Antipsychotics Haloperidol NDA receptor antagonists Cognitive dysfunction Behavioral disturbances Psychosis Deep brain stimulation 



No potential conflicts of interest relevant to this article were reported.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72(6):971–83.Google Scholar
  2. 2.
    Mahant N, McCusker EA, Byth K, Graham S. Huntington's disease: clinical correlates of disability and progression. Neurology. 2003;61(8):1085–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Di Maio L, Squitieri F, Napolitano G, et al. Onset symptoms in 510 patients with Huntington's disease. J Med Genet. 1993;30(4):289–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001;71(3):310–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Litvan I, Paulsen JS, Mega MS, Cummings JL. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch Neurol. 1998;55(10):1313–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Ho AK, Sahakian BJ, Brown RG, et al. Profile of cognitive progression in early Huntington's disease. Neurology. 2003;61(12):1702–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Bamford KA, Caine ED, Kido DK, et al. A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology. 1995;45(10):1867–73.PubMedCrossRefGoogle Scholar
  8. 8.
    Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease. Mov Disord. 2000;15(1):173–6.PubMedCrossRefGoogle Scholar
  9. 9.
    de Tommaso M, Specchio N, Sciruicchio V, et al. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord. 2004;19(12):1516–8.PubMedCrossRefGoogle Scholar
  10. 10.•
    Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366–72. Important recent Class I evidence treatment study on TBZ in HD.CrossRefGoogle Scholar
  11. 11.
    Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009;9:62.PubMedCrossRefGoogle Scholar
  12. 12.
    Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007;22(1):10–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48(2):358–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002;25(6):300–2.PubMedCrossRefGoogle Scholar
  15. 15.
    Koller WC, Trimble J. The gait abnormality of Huntington's disease. Neurology. 1985;35(10):1450–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Girotti F, Carella F, Scigliano G, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J Neurol Neurosurg Psychiatry. 1984;47(8):848–52.PubMedCrossRefGoogle Scholar
  17. 17.
    McArthur AW, Pollock M, Smidt NA. Combined therapy with tetrabenazine and pimozide in Huntington's chorea: pilot study. N Z Med J. 1976;83(558):114–6.PubMedGoogle Scholar
  18. 18.•
    van Vugt JP, Siesling S, Vergeer M, et al. Clozapine vs placebo in Huntington's disease: a double blind randomized comparative study. J Neurol Neurosurg Psychiatry. 1997;63(1):35–9. Class I evidence treatment study on clozapine in HD.PubMedCrossRefGoogle Scholar
  19. 19.
    Bonuccelli U, Ceravolo R, Maremmani C, et al. Clozapine in Huntington's chorea. Neurology. 1994;44(5):821–3.PubMedCrossRefGoogle Scholar
  20. 20.
    Vallette N, Gosselin O, Kahn JP. Efficacy of clozapine in the course of Huntington chorea: apropos of a clinical case. Encephale. 2001;27(2):169–71.PubMedGoogle Scholar
  21. 21.
    Colosimo C, Cassetta E, Bentivoglio AR, Albanese A. Clozapine in Huntington's disease. Neurology. 1995;45(5):1023–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. Clin Neuropharmacol. 2002;25(5):263–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Bogelman G, Hirschmann S, Modai I. Olanzapine and Huntington's disease. J Clin Psychopharmacol. 2001;21(2):245–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Bonelli RM, Niederwieser G, Diez J, Koltringer P. Riluzole and olanzapine in Huntington's disease. Eur J Neurol. 2002;9(2):183–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Bonelli RM, Niederwieser G, Tribl GG, Koltringer P. High-dose olanzapine in Huntington's disease. Int Clin Psychopharmacol. 2002;17(2):91–3.PubMedCrossRefGoogle Scholar
  26. 26.
    Dipple HC. The use of olanzapine for movement disorder in Huntington's disease: a first case report. J Neurol Neurosurg Psychiatry. 1999;67(1):123–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Etchebehere EC, Lima MC, Passos W, et al. Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report. Arq Neuropsiquiatr. 1999;57(3B):863–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Grove Jr VE, Quintanilla J, DeVaney GT. Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med. 2000;343(13):973–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Jimenez-Jimenez FJ, de Toledo M, Puertas I, et al. Olanzapine improves chorea in patients with Huntington's disease. Rev Neurol. 2002;35(6):524–5.PubMedGoogle Scholar
  30. 30.
    Laks J, Rocha M, Capitao C, et al. Functional and motor response to low dose olanzapine in Huntington's disease: case report. Arq Neuropsiquiatr. 2004;62(4):1092–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Bonelli RM, Mayr BM, Niederwieser G, et al. Ziprasidone in Huntington's disease: the first case reports. J Psychopharmacol. 2003;17(4):459–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord. 2009;24(1):126–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatr Dis Treat. 2009;5:1–4.PubMedGoogle Scholar
  34. 34.
    Parsa MA, Szigethy E, Voci JM, Meltzer HY. Risperidone in treatment of choreoathetosis of Huntington's disease. J Clin Psychopharmacol. 1997;17(2):134–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999;19(1):101–3.PubMedCrossRefGoogle Scholar
  36. 36.
    Bonelli RM, Niederwieser G. Quetiapine in Huntington's disease: a first case report. J Neurol. 2002;249(8):1114–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Verhagen Metman L, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;59(5):694–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Lucetti C, Del Dotto P, Gambaccini G, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology. 2003;60(12):1995–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Heckmann JM, Legg P, Sklar D, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology. 2004;63(3):597–8. author reply 597–8.PubMedCrossRefGoogle Scholar
  40. 40.
    O'Suilleabhain P, Dewey Jr RB. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003;60(7):996–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord. 2007;13(7):453–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 2005;65(2):286–92.PubMedCrossRefGoogle Scholar
  43. 43.
    Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008;65(12):1582–9.Google Scholar
  44. 44.
    de Tommaso M, Difruscolo O, Sciruicchio V, et al. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30(1):43–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67(7):1268–71.PubMedCrossRefGoogle Scholar
  46. 46.
    Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease. Mov Disord. 2000;15(1):173–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Como PG, Rubin AJ, O'Brien CF, et al. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord. 1997;12(3):397–401.PubMedCrossRefGoogle Scholar
  48. 48.
    Holl AK, Wilkinson L, Painold A, et al. Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25(1):46–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Bonelli RM. Mirtazapine in suicidal Huntington's disease. Ann Pharmacother. 2003;37(3):452.PubMedCrossRefGoogle Scholar
  50. 50.
    Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. Neurology. 1991;41(1):156.PubMedCrossRefGoogle Scholar
  51. 51.
    Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. Eur J Neurol. 2002;9(2):182–3.PubMedCrossRefGoogle Scholar
  52. 52.
    Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. Am J Geriatr Psychiatry. 1998;6(4):347–9.PubMedGoogle Scholar
  53. 53.
    Squitieri F, Cannella M, Piorcellini A, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(1):69–72.PubMedGoogle Scholar
  54. 54.
    Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand. 2002;105(6):441–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics. 2006;47(1):70–2.PubMedCrossRefGoogle Scholar
  56. 56.
    Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington's disease. J Neuropsychiatry Clin Neurosci. 1996;8(3):338–40.PubMedGoogle Scholar
  57. 57.
    Bhandary AN, Masand PS. Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders. Psychosomatics. 1997;38(4):389–91.PubMedCrossRefGoogle Scholar
  58. 58.
    Byrne A, Martin W, Hnatko G. Beneficial effects of buspirone therapy in Huntington's disease. Am J Psychiatry. 1994;151(7):1097.PubMedGoogle Scholar
  59. 59.
    Findling RL. Treatment of aggression in juvenile-onset Huntington's disease with buspirone. Psychosomatics. 1993;34(5):460–1.PubMedCrossRefGoogle Scholar
  60. 60.
    Stewart JT, Mounts ML, Clark Jr RL. Aggressive behavior in Huntington's disease: treatment with propranolol. J Clin Psychiatry. 1987;48(3):106–8.PubMedGoogle Scholar
  61. 61.
    Stewart JT. Paradoxical aggressive effect of propranolol in a patient with Huntington's disease. J Clin Psychiatry. 1987;48(9):385–6.PubMedGoogle Scholar
  62. 62.
    Kang GA, Heath S, Rothlind J, Starr PA. Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease. J Neurol Neurosurg Psychiatry. 2011;82(3):272–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Biolsi B, Cif L, Fertit HE, et al. Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. J Neurosurg. 2008;109(1):130–2.PubMedCrossRefGoogle Scholar
  64. 64.
    Fasano A, Mazzone P, Piano C, et al. GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case. Mov Disord. 2008;23(9):1289–92.PubMedCrossRefGoogle Scholar
  65. 65.
    Moro E, Lang AE, Strafella AP, et al. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol. 2004;56(2):290–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Neurology, Parkinson’s Disease and Movement Disorders CenterNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations